StockNews.AI
JAGX
StockNews.AI
197 days

Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025

1. Crofelemer received Orphan Drug Designation for SBS-IF and MVID in the US and EU. 2. First patients dosed in pediatric trial, indicating progress in rare disease treatment.

3m saved
Insight
Article

FAQ

Why Bullish?

The Orphan Drug Designation can enhance market potential and investor confidence. Previous FDA approvals have positively influenced stock performance in the biopharma sector.

How important is it?

The article discusses significant trial progress, which can directly affect JAGX's market perception and valuation.

Why Short Term?

Immediate progress in patient dosing may attract investor interest. Short-term advancements typically impact stock prices quickly.

Related Companies

JAGXNPOJAGX-L
Trial taking place at Sheikh Khalifa Medical City , a flagship United Arab Emirates hospital and largest teaching medical center in Abu Dhabi Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both SBS-IF and MVID Proof-of-concept (POC) data generated from this study could potentially lead to reimbursed early patient access in certain European countries for crofelemer for these rare/orphan diseases SAN FRANCISCO, CA / ACCESS Newswire / February 3, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that the first short bowel syndrome with intestinal failure (SBS-IF) patient has been dosed in the independent investigator-initiated pediatric POC trial (IIT) of crofelemer, Jaguar's novel plant-based antidiarrheal prescription drug. The first infant with microvillus inclusion disease (MVID) was dosed as part of the same IIT two weeks ago.

Related News